EUVIMEDEUVIMED entdecken
Crossref

Position Statement of the Immunonephrology Working Group of the Portuguese Society of Nephrology on the Use of Belimumab in Lupus Nephritis

Estela Nogueira, Nuno A Oliveira, Iolanda Godinho, Alice Lança, António da Silva Inácio, Clara Santos, Pinto, Helena, Ivo Laranjinha, Raquel Vaz, Oliveira Correia, Sofia und 3 weitere

Portuguese Kidney Journal (PKJ) · 28.03.2025

DOI: 10.71749/pkj.89 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Portuguese Kidney Journal (PKJ), erschienen am 28.03.2025. Verfasst von Estela Nogueira und 14 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a challenging immune ‑mediated disease that frequently involves the kidney as lupus nephritis (LN), an immune complex glomerulonephritis. Its occurrence is associated with increased morbidity and mortality and current treatment still fails to preserve renal function in the long term. As such, more efficacious and less toxic treatments are needed to treat LN, aiming to reduce renal relapses and improve renal survival. Belimumab, an inhibitor of the soluble B ‑cell activating factor became the first biologic agent approved for the treatment of SLE and is now approved as an add ‑on therapy for LN. Herein, the Immunonephrology Working Group of the Portuguese Society of Nephrology reviewed the scientific evidence that led to belimumab´s approval in recent LN guidelines and exposed its perspective on the use of belimumab in LN in Portugal.

Schlagwörter

belimumablupus nephritissystemic lupus erythematosusB-cell activating factorB-cell depletionadjunctive therapyimmune complex glomerulonephritisrenal relapserenal survivaltreatment guidelines

Zitieren

APA

Nogueira, E., Oliveira, N. A., Godinho, I., Lança, A., Inácio, A. D. S., Santos, C., Pinto, Helena, Laranjinha, I., Vaz, R., Correia, O., Sofia, Jerónimo, T. M., Ferreira, & Inês (2025). Position Statement of the Immunonephrology Working Group of the Portuguese Society of Nephrology on the Use of Belimumab in Lupus Nephritis. Portuguese Kidney Journal (PKJ). https://doi.org/10.71749/pkj.89

Vancouver

Nogueira E, Oliveira NA, Godinho I, Lança A, Inácio ADS, Santos C, et al. Position Statement of the Immunonephrology Working Group of the Portuguese Society of Nephrology on the Use of Belimumab in Lupus Nephritis. Portuguese Kidney Journal (PKJ). 2025. doi:10.71749/pkj.89

BibTeX
@article{Nogueira2025,
  author = {Nogueira, Estela and Oliveira, Nuno A and Godinho, Iolanda and Lança, Alice and Inácio, António da Silva and Santos, Clara and Pinto and Helena and Laranjinha, Ivo and Vaz, Raquel and Correia, Oliveira and Sofia and Jerónimo, Teresa M. and Ferreira and Inês},
  title = {Position Statement of the Immunonephrology Working Group of the Portuguese Society of Nephrology on the Use of Belimumab in Lupus Nephritis},
  journal = {Portuguese Kidney Journal (PKJ)},
  year = {2025},
  doi = {10.71749/pkj.89}
}
Kostenlos starten →